List view / Grid view
In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.
Using computer modelling, a team has shown that a molecular chaperone called GRP78 could be targeted by drugs in strategies to treat COVID-19.
Researchers have successfully created an unbiased, high-throughput microtitration assay for the quantification of Ebola virus in cell lines.
Researchers have designed a new nanoparticle-based vaccine against Ebola that has shown promise in mice and rabbits.
Professor Martin Michaelis and Dr Mark Wass explain why new SARS-CoV-2 variants are emerging around the world and how vaccines will have to adapt in response.
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
![A coiling protein 'shell,' called a nucleocapsid, shown here, surrounds Ebola's genetic material, which consists of single-strand RNA. University of Delaware researchers are simulating the way molecules of this nucleocapsid move and interact, atom by atom, to understand their functions and expose targets for anti-viral treatments [Credit: Juan Perilla Laboratory].](https://drug.russellpublishing.co.uk/wp-content/uploads/Ebola-nucleocapsid-e1603365997854.jpg)
Using supercomputer stimulations researchers reveal that the structural stability of the Ebola nucleocapsid is depended on the presence of RNA and interactions with charged ions.
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://drug.russellpublishing.co.uk/wp-content/uploads/remdesivir-SARS-CoV-2-750x500.jpg)
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://drug.russellpublishing.co.uk/wp-content/uploads/remdesivir-SARS-CoV-2-scaled-e1602154798857.jpg)
Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
The global network of centers will investigate where pathogens emerge and how they adapt to cause disease in humans, in the hopes of increasing our preparedness for future disease outbreaks.
Researchers reveal that activating the MHC class II transactivator (CIITA) and CD74 genes protected cells against infection by Ebola and SARS-CoV-2.
Researchers discovered the monoclonal antibodies of a convalescent Marburg infection patient bound to the glycoprotein and combatted infection in two novel ways.
An innovative chimeric vaccine containing an Ebola gene that helps the virus evade the immune system has been used to selectively target and kill glioblastoma in mice.
A study has described a two-antibody cocktail medication that has been successful in vivo italics trials and could treat Ebola in one dose...
A study has found that the human protein, RBBP6, helps fight Ebola virus by interfering with the virus replication cycle…
Researchers collaborated to identify the clearest image of the Ebola virus protein ever obtained using a cryo-electron microscope...
